Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K35/76

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/204714ZINC-BASED PHYSIONANOCOMPOSITES AND METHODS OF USE THEREOF
WO 29.09.2022
Int.Class A01N 59/16
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
59Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
16Heavy metals; Compounds thereof
Appl.No PCT/US2022/071334 Applicant KANSAS STATE UNIVERSITY RESEARCH FOUNDATION Inventor DELONG, Robert
The present disclosure provides ZnS-based compositions that treat cancer and viral infections. The ZnS compositions can further include manganese or iron and/or be doped with manganese (Mn), iron (Fe), nickel (Ni), cobalt Co), cobalt ferrite (CoFe), and any combination thereof.
2.WO/2022/204434TRANSCRIPTIONAL AND TRANSLATIONAL DUAL REGULATED ONCOLYTIC HERPES SIMPLEX VIRUS VECTORS
WO 29.09.2022
Int.Class A61K 35/763
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
763Herpes virus
Appl.No PCT/US2022/021798 Applicant VIROGIN BIOTECH CANADA LTD Inventor JIA, William, Wei-Guo
A herpes virus vector is provided with both transcriptional and translational control. Within various embodiments the herpes virus vector is based upon a modified herpes virus and has both ICP27 and ICP34.5 under control of a CEA promoter and miRNA-124/143, respectively, and deletion of at least one copy of terminal repeat long region is provided to increase safety without sacrificing efficacy. The herpes virus vector can also incorporate a virus-expressed cytokine cassette encoding IL-12, IL-15/IL-15RA under the control of CXCR4 promoter.
3.WO/2022/203117ONCOLYTIC VIRUS FOR TREATING BRAIN TUMORS BY USING NEWCASTLE DISEASE VIRUS VECTOR-BASED RECOMBINANT NEWCASTLE DISEASE VIRUS INTO WHICH PTEN GENE IS INSERTED, AND COMPOSITION FOR TREATING BRAIN TUMOR BY USING SAME
WO 29.09.2022
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
Appl.No PCT/KR2021/006924 Applicant LIBENTECH CO.,LTD. Inventor JANG, Hyun
The present invention relates to an oncolytic virus for treating brain tumors by using a Newcastle disease virus vector-based recombinant Newcastle disease virus (NDV) into which a phosphatase and tensin homolog (PTEN) gene is inserted, and a composition for treating brain tumors by using same. It has been identified that the PTEN gene is included in the Newcastle disease virus, which can be spread to the human brain, for the purpose of treating brain tumors caused by a PTEN gene abnormality, so that if same is used, PTEN protein is expressed in cancer cells, and thus brain tumors can be treated through brain tumor cell death. Therefore, the present invention relates to a therapeutic viral preparation, which is a recombinant Newcastle disease virus comprising a human PTEN protein gene, the preparation being capable of reducing clinical symptoms or inducing partial or complete remission through brain tumor cell death or brain tumor tissue shrinkage by infecting brain tumor cells and expressing normal PTEN protein.
4.4063859BIOMARKERS FOR CANCER THERAPEUTICS
EP 28.09.2022
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Appl.No 22163106 Applicant MERCK SHARP & DOHME Inventor GANSERT JENNIFER LORRAINE
Biomarkers useful for identifying a variety of cancers that are responsive to treatment with a combination therapy comprising pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof and talimogene laherparepvec are provided. Methods of treating cancers that are resistant to monotherapy with pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof are provided. Methods of treating a cancer in a subject having a tumor with a low CD8+ density, a low or negative interferon gamma signature, and/or a low or negative PD-L1 status are also provided.
5.20220296710MODULAR PHAGE VECTOR PLATFORM FOR SONODYNAMIC THERAPY
US 22.09.2022
Int.Class A61K 41/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
41Medicinal preparations obtained by treating materials with wave energy or particle radiation
Appl.No 17596746 Applicant ALMA MATER STUDIORUM - Universita' di Bologna Inventor Alberto Danielli

The present invention relates to a phage or a composition that comprises it, wherein said phage expresses at least one specific recognition element and is furthermore conjugated with at least 300 molecules of a sonosensitiser. The invention further relates to the use of said phage in a sonodynamic therapy.

6.WO/2022/198002ARTIFICIAL ALPHAVIRUS-DERIVED RNA REPLICON EXPRESSION SYSTEMS
WO 22.09.2022
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No PCT/US2022/020881 Applicant TIBA BIOTECH LLC Inventor CHAHAL, Jasdave S.
Synthetic alphavirus-derived replicon expression systems comprising nucleic acid sequences encoding at least one modified nonstructural protein, and synthetic nucleic acid sequences encoding at least one heterologous protein are described. Methods of producing at least one heterologous protein in a cell, or of inducing an immune response in a subject by administering and/or expressing the synthetic alphavirus-derived replicon expression systems are provided.
7.WO/2022/197878A CLOSED-SYSTEM UPSTREAM MANUFACTURING PROCESS FOR DENGUE VIRUS PRODUCTION
WO 22.09.2022
Int.Class C12N 7/02
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
02Recovery or purification
Appl.No PCT/US2022/020676 Applicant MERCK SHARP & DOHME LLC Inventor CHADHA, Pooja
The instant invention discloses a closed-system, serum-free, microcarrier-based up-stream process to produce dengue virus. The process comprises a closed-system cell expansion comprising cell passages taking place in closed-system containers. These cell expansions represent a closed process, with replacement media, a cell-detachment agent, and quench medium added though sterile, weldable tubing (a closed-system environment) to eliminate all open aseptic processing following the initial vial thaw of the adherent cells. The viral production takes place in a closed-system bioreactor in adherent cell culture grown on microcarriers providing sufficient cell mass to support the production of dengue virus.
8.WO/2022/198091MICROBIOME IDENTIFICATION AND BACTERIOPHAGE FORMULATIONS
WO 22.09.2022
Int.Class C12Q 1/6888
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6888for detection or identification of organisms
Appl.No PCT/US2022/021021 Applicant PARALLEL HEALTH, INC. Inventor BROWN, Nathan
Provided herein are methods for treating a health condition of a subject. The method may comprise detection of a microorganism in a sample from the subject and, subsequent to identification of the microorganism, generating a bacteriophage mixture comprising at least one bacteriophage capable of lysing the microorganism. One or more processes described herein may comprise shotgun metagenomic sequencing.
9.WO/2022/196719GENE CODING FOR CHIMERIC RECEPTOR FOR ANTI-ACETYLCHOLINE RECEPTOR AUTOANTIBODY
WO 22.09.2022
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
Appl.No PCT/JP2022/011820 Applicant DAIICHI SANKYO COMPANY, LIMITED Inventor YOSHIKIYO Kazunori
The present invention provides: a chimeric receptor polypeptide which is useful in treatment of myasthenia gravis and in which an extracellular domain that includes an antigenic region linkable to an anti-human nicotinic acetylcholine receptor α1 sub-unit (nAChRα1) antibody, a cell transmembrane region, and an intracellular domain that includes an intracellular signal transduction region are disposed in this order from the N-terminus to the C-terminus (where the amino acid sequence of the antigenic region is that of SEQ ID NO: 2, or a region including an amino acid sequence in which one or more amino acids have been substituted, deleted, inserted, and/or added in the amino acid sequence of SEQ ID NO: 2); a polynucleotide which codes for the chimeric receptor polypeptide; and a cell which expresses the chimeric receptor polypeptide.
10.11446344Anellovirus compositions and methods of use
US 20.09.2022
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No 17489652 Applicant FLAGSHIP PIONEERING INNOVATIONS V, INC. Inventor Simon Delagrave

This invention relates generally to viral vectors and viral particles based on Anelloviruses, which can be used to deliver an agent (e.g., an exogenous effector or an endogenous effector, e.g., a therapeutic effector) to a cell (e.g., a cell in a subject to be treated therapeutically). Described herein are anellosomes, anellovectors, and compositions and uses thereof.